Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT04948008

Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia

A Seamless Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia in China

Sponsor: Shenzhen People's Hospital

Conditions Familial Hypercholesterolemia - Homozygous Lipid Metabolism Disorders Proprotein Convertase Subtilisin/Kexin 9

Interventions IBI306

Updated 4 times since 2021 Last updated: Jun 29, 2021 Started: Nov 5, 2019 Primary completion: Jul 15, 2020 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Familial Hypercholesterolemia - Homozygous and Lipid Metabolism Disorders and is currently ongoing. Shenzhen People's Hospital leads this study, which shows 4 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jul 2023 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3

Status: Recruiting → Unknown Status
Sep 2021 — Jul 2023 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Nov 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shenzhen People's Hospital

Data source: Shenzhen People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shenzhen, China